Researchmoz Global Pvt. Ltd.

Global Immunology Industry Trend, Growth, Size, Share and Forecast to 2022 - Large Pipeline and Competitive Market

Researchmoz added Most up-to-date research on "Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth" to its huge collection of research reports.


Albany, NY -- (SBWIRE) -- 01/28/2016 -- Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

To Get Sample Copy of Report visit @


Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.

What factors are driving the market growth?
How can the factors limiting growth be overcome?

There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.

What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
How does the composition of the pipeline compare with that of the existing market?

Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.

How will this affect their revenues in this period?
How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?

The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.

What is driving this continued market dominance?
Who will the new market players be?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Browse Detail Report With TOC @

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 Therapy Area Introduction 8
2.2 Symptoms 8
2.3 Etiology and Pathophysiology 9
2.4 Co-morbidities and Complications 11
2.5 Epidemiology Patterns and Forecasts – Prevalence, Patient Segmentation, Diagnostic and Treatment Usage Rates 11
2.5.1 Rheumatoid Arthritis 12
2.5.2 Psoriasis 13
2.5.3 Systemic Lupus Erythematosus 14
2.6 Treatment 15
2.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs 16
2.6.2 Glucocorticoids 17
2.6.3 Biologics 17
3 Key Marketed Products 19
3.1 Overview 19
3.2 Humira (adalimumab) 21
3.3 Remicade (infliximab) 22
3.4 Enbrel (etanercept) 24
3.5 Rituxan (rituximab) 26
3.6 Stelara (ustekinumab) 27
3.7 Prograf (tacrolimus) 28
3.8 Cimzia (certolizumab pegol) 30
3.9 Simponi (golimumab) 31
3.10 Conclusion 33
4 Pipeline Landscape Assessment 34
4.1 Overview 34
4.2 Pipeline Development Landscape 34
4.3 Molecular Targets in the Pipeline 37
4.4 Clinical Trials 39
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 40
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 43
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 47
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 51
4.5 Conclusion 56
5 Multi-Scenario Market Forecast to 2022 57
5.1 Overall Market Size 57
5.2 Generic Penetration 60
5.3 Revenue Forecast by Molecular Target 61
5.3.1 Tumor Necrosis Factor-Alpha 62
5.3.2 Interleukin-6 and Interleukin-6 Receptor 63
5.3.3 Interleukins-1, 2, 5, 12, 17 and 23 and Receptors 63
5.3.4 Janus Kinases 64
5.3.5 Revenue and Market Share Analysis by Company 65
5.3.6 Assessment of Key Pipeline Products 74

Make an Enquiry of this report @

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Browse Our Latest Press Releases @